This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Alimera Sciences Stock (NASDAQ:ALIM) 30 days 90 days 365 days Advanced Chart Get Alimera Sciences alerts:Sign Up Key Stats Today's Range$5.54▼$5.5450-Day Range$5.19▼$5.6052-Week Range$2.61▼$5.65VolumeN/AAverage Volume376,318 shsMarket Capitalization$290.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Read More Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALIM Stock News HeadlinesAlimera Sciences Inc.March 19, 2025 | money.usnews.comANI Pharmaceuticals’ Record Growth and Strategic AcquisitionNovember 9, 2024 | markets.businessinsider.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.August 28 at 2:00 AM | Porter & Company (Ad)ANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target PriceSeptember 18, 2024 | markets.businessinsider.comAlimera Sciences, Inc. (NASDAQ:ALIM): When Will It Breakeven?September 12, 2024 | finance.yahoo.comAlimera Sciences, Inc. (ALIM)September 11, 2024 | finance.yahoo.comAlimera Sciences: Deal Closing After All, CVR Still AttractiveSeptember 11, 2024 | seekingalpha.comANI Pharmaceuticals, Alimera Sciences deal set to close MondaySeptember 11, 2024 | msn.comSee More Headlines ALIM Stock Analysis - Frequently Asked Questions How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) issued its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.02. The biopharmaceutical company had revenue of $27 million for the quarter, compared to the consensus estimate of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative trailing twelve-month return on equity of 33.70%. When did Alimera Sciences' stock split? Shares of Alimera Sciences reverse split on the morning of Friday, November 15th 2019.The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alimera Sciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/06/2024Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALIM CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees150Year Founded2003Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.13 million Net Margins-14.74% Pretax Margin-14.76% Return on Equity-33.70% Return on Assets-9.63% Debt Debt-to-Equity Ratio1.80 Current Ratio2.79 Quick Ratio2.62 Sales & Book Value Annual Sales$99.68 million Price / Sales2.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book6.30Miscellaneous Outstanding Shares52,389,000Free Float35,939,000Market Cap$290.24 million OptionableOptionable Beta1.25 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ALIM) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alimera Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.